Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. (301096.SZ) Latest Company News

Oct 23, 2026, 09:00 UTC
Hangzhou Baijing Biotechnology Co., Ltd. (provisional name) plans to establish a joint venture with Shenzhen Zhiyào Technology Co., Ltd., with Baicheng Pharmaceutical contributing RMB 14 million for a 70% stake and Zhiyào Technology contributing RMB 6 million for a 30% stake.
Source:
- finance.sina.cn
Oct 23, 2026, 08:59 UTC
Hangzhou BioCrystal Biotechnology Co., Ltd. (provisional name) plans to establish a joint venture with Shenzhen Zhiyào Technology Co., Ltd., with Baicheng Pharmaceutical contributing RMB 14 million for a 70% stake and Zhiyào Technology contributing RMB 6 million for 30%.
Source:
- finance.sina.cn
Oct 14, 2026, 02:46 UTC
Shenzhen Dafor Pharmaceutical Co., Ltd., Hangzhou Mipeng Enterprise Management Partnership and other shareholders established Hangzhou Xinnanye Pharmaceutical Technology Co., Ltd. with registered capital of 50 million yuan.
Source:
- finance.sina.cn
Aug 26, 2026, 10:24 UTC
Baicheng Pharmaceutical announced its 2026 first-half results: revenue of 304 million yuan, down 8.40% year-on-year; net profit attributable to shareholders of 1.5977 million yuan, down 48.43% year-on-year; and a plan not to distribute dividends or convert capital reserves.
Source:
- finance.sina.cn
Aug 11, 2026, 09:17 UTC
Baicheng Pharmaceutical's subsidiary Zhejiang Saimei Pharmaceutical won a bid in the 12th national centralized drug procurement for its sitagliptin and metformin extended-release tablets.
Source:
- finance.sina.cn
Jul 27, 2026, 08:08 UTC
Baicheng Pharmaceutical received clinical trial approval notice from the National Medical Products Administration for its self-developed innovative drug BIOS0635-048 tablets.
Source:
- finance.sina.cn
Jul 17, 2026, 09:12 UTC
Baicheng Pharmaceutical's wholly-owned subsidiary Zhejiang Saimei Pharmaceutical Co., Ltd. received a drug registration certificate from the National Medical Products Administration for its class 2.2 modified new drug Levetiracetam Extended-Release Granules.
Source:
- finance.sina.cn
- finance.sina.cn
Jul 15, 2026, 01:41 UTC
Baicheng Pharmaceutical and others established a new medical technology company, Zhejiang Wusheng Medical Technology Co., Ltd.
Source:
- finance.sina.cn

301096.SZ

Hangzhou Baijing Biotechnology Co., Ltd. (provisional name) plans to establish a joint venture with Shenzhen Zhiyào Technology Co., Ltd., with Baicheng Pharmaceutical contributing RMB 14 million for a 70% stake and Zhiyào Technology contributing RMB 6 million for a 30% stake.

Hangzhou BioCrystal Biotechnology Co., Ltd. (provisional name) plans to establish a joint venture with Shenzhen Zhiyào Technology Co., Ltd., with Baicheng Pharmaceutical contributing RMB 14 million for a 70% stake and Zhiyào Technology contributing RMB 6 million for 30%.

Shenzhen Dafor Pharmaceutical Co., Ltd., Hangzhou Mipeng Enterprise Management Partnership and other shareholders established Hangzhou Xinnanye Pharmaceutical Technology Co., Ltd. with registered capital of 50 million yuan.

Baicheng Pharmaceutical announced its 2026 first-half results: revenue of 304 million yuan, down 8.40% year-on-year; net profit attributable to shareholders of 1.5977 million yuan, down 48.43% year-on-year; and a plan not to distribute dividends or convert capital reserves.

Baicheng Pharmaceutical's subsidiary Zhejiang Saimei Pharmaceutical won a bid in the 12th national centralized drug procurement for its sitagliptin and metformin extended-release tablets.

Baicheng Pharmaceutical received clinical trial approval notice from the National Medical Products Administration for its self-developed innovative drug BIOS0635-048 tablets.

Baicheng Pharmaceutical's wholly-owned subsidiary Zhejiang Saimei Pharmaceutical Co., Ltd. received a drug registration certificate from the National Medical Products Administration for its class 2.2 modified new drug Levetiracetam Extended-Release Granules.

Baicheng Pharmaceutical and others established a new medical technology company, Zhejiang Wusheng Medical Technology Co., Ltd.